These inhibitors include the mutant IDH2 inhibitor AG-221 (enasidenib), and mutant IDH1 inhibitorAG-120 (ivosidenib), which have been extensively investigated for the treatment of patients with AML or MDS with a susceptible IDH mutation [142]. This evidence concerns the gene IDH1 and myelodysplastic syndrome.